[go: up one dir, main page]

EE04551B1 - Optiliselt aktiivne pridl-4H-1,2,4-oksadiasiini derivaat ja selle kasutamine vaskulaarsete haiguste ravis - Google Patents

Optiliselt aktiivne pridl-4H-1,2,4-oksadiasiini derivaat ja selle kasutamine vaskulaarsete haiguste ravis

Info

Publication number
EE04551B1
EE04551B1 EEP200100188A EEP200100188A EE04551B1 EE 04551 B1 EE04551 B1 EE 04551B1 EE P200100188 A EEP200100188 A EE P200100188A EE P200100188 A EEP200100188 A EE P200100188A EE 04551 B1 EE04551 B1 EE 04551B1
Authority
EE
Estonia
Prior art keywords
treatment
optically active
vascular diseases
active piperidine
oxadiazine derivative
Prior art date
Application number
EEP200100188A
Other languages
English (en)
Estonian (et)
Inventor
Jedn�kovits Andrea
�r�gdi L�szl�
D�nes L�szl�
Kurucz Istv�n
M�rv�nyos Ede
Barab�s Mih�ly
B�csy Ern�
Korom Zsuzsanna
Nagy Zolt�n
�rge L�szl�
Szilbereky Jen�
Acsai K�roly
Krajcsi P�ter
Cs�kai Zita
T�r�k Magdolna
Original Assignee
Biorex Kutat� �s Fejleszto Rt.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biorex Kutat� �s Fejleszto Rt. filed Critical Biorex Kutat� �s Fejleszto Rt.
Publication of EE200100188A publication Critical patent/EE200100188A/xx
Publication of EE04551B1 publication Critical patent/EE04551B1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Cardiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
EEP200100188A 1998-12-14 1999-12-07 Optiliselt aktiivne pridl-4H-1,2,4-oksadiasiini derivaat ja selle kasutamine vaskulaarsete haiguste ravis EE04551B1 (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
HU9802897A HU226617B1 (en) 1998-12-14 1998-12-14 Optically active pyridyl-4h-1,2,4-oxadiazine derivatives, and pharmaceutical composition containing the compound as active ingredient
PCT/HU1999/000095 WO2000035914A1 (en) 1998-12-14 1999-12-07 Optically active pyridyl-4h-1,2,4-oxadiazine derivative and its use in the treatment of vascular diseases

Publications (2)

Publication Number Publication Date
EE200100188A EE200100188A (et) 2002-08-15
EE04551B1 true EE04551B1 (et) 2005-10-17

Family

ID=10991166

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200100188A EE04551B1 (et) 1998-12-14 1999-12-07 Optiliselt aktiivne pridl-4H-1,2,4-oksadiasiini derivaat ja selle kasutamine vaskulaarsete haiguste ravis

Country Status (27)

Country Link
US (1) US6384029B1 (xx)
EP (1) EP1147105B1 (xx)
JP (2) JP2002532498A (xx)
KR (1) KR100661774B1 (xx)
AT (1) ATE266027T1 (xx)
AU (1) AU765336B2 (xx)
BG (1) BG65179B1 (xx)
BR (1) BR9913982A (xx)
CA (1) CA2340734C (xx)
CZ (1) CZ300764B6 (xx)
DE (1) DE69917074T2 (xx)
DK (1) DK1147105T3 (xx)
EE (1) EE04551B1 (xx)
ES (1) ES2219091T3 (xx)
HR (1) HRP20010133B1 (xx)
HU (1) HU226617B1 (xx)
IL (1) IL141515A (xx)
NO (1) NO317649B1 (xx)
PL (1) PL196584B1 (xx)
PT (1) PT1147105E (xx)
RS (1) RS50129B (xx)
RU (1) RU2222538C2 (xx)
SI (1) SI1147105T1 (xx)
SK (1) SK285582B6 (xx)
UA (1) UA70340C2 (xx)
WO (1) WO2000035914A1 (xx)
ZA (1) ZA200101182B (xx)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005514418A (ja) 2002-01-11 2005-05-19 ビオレックス クタトー エス フェイレストェー アールテー． カルボキサミジン誘導体及び血管疾患の治療におけるそれらの使用
KR100678577B1 (ko) * 2006-09-11 2007-02-06 조만규 가정용 분전함
CA3004867C (en) 2008-06-26 2020-09-15 Orphazyme Aps Use of hsp70 as a regulator of enzymatic activity
WO2010058779A1 (ja) 2008-11-18 2010-05-27 参天製薬株式会社 ピリジン－３－カルバルデヒド ｏ－（ピペリジン－１－イル－プロピル）－オキシム誘導体を有効成分として含有する網脈絡膜変性疾患の治療剤
JP2013544263A (ja) 2010-11-30 2013-12-12 オルファザイム エーピーエス Ｈｓｐ７０の細胞内活性を上昇させる方法
HUP1100534A2 (en) 2011-09-26 2013-04-29 Balazs Dr Hazay Pharmaceutical composition for the treatment of muscle atrophy
JP6678676B2 (ja) 2014-09-15 2020-04-08 オーファザイム エー／エス アリモクロモル製剤
EP3442530A1 (en) 2016-04-13 2019-02-20 Orphazyme A/S Heat shock proteins and cholesterol homeostasis
PT3448382T (pt) 2016-04-29 2020-11-20 Orphazyme As C/O Cobis As Arimoclomol para o tratamento de distúrbios associados à glucocerebrosidase
AU2018274176A1 (en) 2017-05-24 2020-01-16 Zevra Denmark A/S Heat shock protein inducers and frontotemporal disorders
BR112020024182A2 (pt) 2018-05-28 2021-03-30 Orphazyme A/S Métodos para detectar proteína de choque térmico 70, para diagnosticar uma doença apresentando um nível reduzido de proteína de choque térmico 70, para selecionar um paciente tendo uma doença apresentando um nível reduzido de hsp70, para monitorar progressão de doença em um indivíduo, para monitorar a eficácia de uma terapia para tratamento de uma doença, e, para ajustar a dosagem de um derivado de hidroxilamina de molécula pequena.
IL303026A (en) 2020-11-19 2023-07-01 Zevra Denmark As Processes for preparing arimoclomol citrate and intermediates thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT395853B (de) * 1991-01-31 1993-03-25 Chem Pharm Forsch Gmbh Neue imidazolderivate, verfahren zu ihrer herstellung und ihre verwendung
HU222994B1 (hu) * 1995-11-02 2004-01-28 BIOREX Kutató és Fejlesztő Rt. Hidroxilaminszármazékok és azok alkalmazása sejtek molekuláris chaperon-termelésének fokozására alkalmas gyógyszerkészítmények előállítására
AU7324196A (en) * 1995-11-03 1997-05-22 Global Trading Uk Limited Apparatus for dispensing and filling bags at a checkout counter of a supermarket
UA64716C2 (en) * 1996-08-09 2004-03-15 Pharmaceuticals for therapy or prevention of illnesses connected with dysfunction of vascular endothelial cells

Also Published As

Publication number Publication date
HU9802897D0 (en) 1999-02-01
HUP9802897A3 (en) 2001-08-28
KR100661774B1 (ko) 2006-12-28
ZA200101182B (en) 2002-02-12
PL346767A1 (en) 2002-02-25
ES2219091T3 (es) 2004-11-16
PT1147105E (pt) 2004-07-30
NO20012310D0 (no) 2001-05-10
UA70340C2 (en) 2004-10-15
RU2222538C2 (ru) 2004-01-27
SI1147105T1 (en) 2004-08-31
CZ300764B6 (cs) 2009-08-05
EE200100188A (et) 2002-08-15
AU1790600A (en) 2000-07-03
DK1147105T3 (da) 2004-06-01
KR20010073129A (ko) 2001-07-31
US6384029B1 (en) 2002-05-07
NO20012310L (no) 2001-05-10
HRP20010133A2 (en) 2002-02-28
CA2340734A1 (en) 2000-06-22
NO317649B1 (no) 2004-11-29
PL196584B1 (pl) 2008-01-31
SK2342001A3 (en) 2001-08-06
HU226617B1 (en) 2009-04-28
EP1147105B1 (en) 2004-05-06
BG105342A (en) 2001-12-29
EP1147105A1 (en) 2001-10-24
YU25001A (sh) 2004-07-15
JP2011201916A (ja) 2011-10-13
BG65179B1 (bg) 2007-05-31
ATE266027T1 (de) 2004-05-15
JP5620340B2 (ja) 2014-11-05
DE69917074T2 (de) 2005-05-12
IL141515A (en) 2005-09-25
SK285582B6 (sk) 2007-04-05
AU765336B2 (en) 2003-09-18
DE69917074D1 (de) 2004-06-09
IL141515A0 (en) 2002-03-10
CZ20011550A3 (cs) 2001-08-15
HUP9802897A2 (hu) 2000-11-28
CA2340734C (en) 2008-10-21
WO2000035914A1 (en) 2000-06-22
RS50129B (sr) 2009-03-25
BR9913982A (pt) 2001-06-12
HRP20010133B1 (en) 2005-02-28
JP2002532498A (ja) 2002-10-02

Similar Documents

Publication Publication Date Title
BG106825A (en) Substituted oxazolidinones and their use in the field of blood coagulation
DE69108048D1 (de) Derivate von hydroxaminsäure und von n-hydroxyharnstoff sowie ihre verwendung.
NO20093464L (no) Nye medikamentblandinger basert pa anti-cholinergisk effektive forbindelser og beta-mimetika
EE03969B1 (et) (Metüülsulfonüül)fenüül-2-(5H)-furanoonid, nende kasutamine ja farmatseutilised kompositsioonid
SE7903186L (sv) Cerebralverksamt medel
ATE218581T1 (de) Cyclosporinderivat, dessen herstellung und pharmazeutische zusammensetzung
BR9807950A (pt) Composto, composição farmacêutica, uso de um composto, e, processos para tratar ou reduzir o risco de doenças ou condições humanas, o risco de doença inflamatória o risco da dor e para a preparação de um composto
EE04551B1 (et) Optiliselt aktiivne pridl-4H-1,2,4-oksadiasiini derivaat ja selle kasutamine vaskulaarsete haiguste ravis
ATE369348T1 (de) Zyklisierte benzamid-neurokinin-antagonisten zur verwendung in therapie
NO982863L (no) Nye forbindelser med analgetisk effekt
TR199901385T2 (xx) Piperidin t�revleri.
ATE110714T1 (de) Derivate von hydroxaminsäure die lipoxygenase hemmen.
BG105984A (bg) Използване на озанетант за приготвяне на лекарствени средства полезни за лечение на разстройства на настроението
DE59101818D1 (de) Arzneimittelzubereitung, enthaltend Stigmasta-4-en-3-on sowie deren Verwendung.
HU9802896D0 (en) Optically active piperidinoalkyl-4h-1,2,4-oxadiazine derivative, the use thereof in the treatment of vascular diseases and pharmaceutical composition containing the compound as active ingredient
TR200000916T2 (tr) İkameli piperidin türevleri.
UA30143C2 (uk) Лікувальний препарат для профілактики та лікування інфекційних та запальних захворювань

Legal Events

Date Code Title Description
KB4A Valid patent at the end of a year

Effective date: 20051231

GB1A Change in the ownership or in the address of the owner
KB4A Valid patent at the end of a year

Effective date: 20061231

KB4A Valid patent at the end of a year

Effective date: 20071231

KB4A Valid patent at the end of a year

Effective date: 20081231

KB4A Valid patent at the end of a year

Effective date: 20101231

MM4A Lapsed by not paying the annual fees

Effective date: 20111207